Stockscreener 앱 받기
0.2635
2.41%
0.0062
시장 영업 전:
.24
-0.0235
-8.92%
전일 마감가:
$0.2573
열려 있는:
$0.255
하루 거래량:
1.01M
Relative Volume:
0.64
시가총액:
$17.96M
수익:
-
순이익/손실:
$-18.65M
주가수익비율:
-0.6002
EPS:
-0.439
순현금흐름:
$-16.66M
1주 성능:
+1.15%
1개월 성능:
+0.08%
6개월 성능:
-51.18%
1년 성능:
-76.05%
1일 변동 폭
$0.24
$0.2699
1주일 범위
$0.24
$0.27
52주 변동 폭
$0.2201
$1.53
Fibrobiologics Inc Stock (FBLG) Company Profile
명칭
Fibrobiologics Inc
전화
281-671-5150
주소
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.2635 | 17.54M | 0 | -18.65M | -16.66M | -0.439 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-30 | 개시 | H.C. Wainwright | Buy |
| 2024-09-24 | 개시 | Maxim Group | Buy |
Fibrobiologics Inc 주식(FBLG)의 최신 뉴스
FibroBiologics stock tumbles on reverse stock split plan By Investing.com - Investing.com Australia
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement - Bitget
FibroBiologics announces 1-for-20 reverse stock split - Investing.com
FibroBiologics announces reverse stock split to regain compliance with Nasdaq's bid price requirement - marketscreener.com
To keep Nasdaq listing, FibroBiologics enacts 1-for-20 split - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
If You Invested $1,000 in Fibrobiologics (FBLG) - Stock Titan
FibroBiologics, Inc.: Fundamental Analysis and Financial Ratings | SG0 | US31573L1052 - marketscreener.com
FBLG SEC FilingsFibrobiologics 10-K, 10-Q, 8-K Forms - Stock Titan
FBLG Forecast, Price Target & Analyst Ratings | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
FibroBiologics, Inc. 2025 Executive Compensation and Leadership Overview - Minichart
FibroBiologics (NASDAQ: FBLG) adds 2025 governance, pay and ownership details - Stock Titan
FibroBiologics: CYWC628 Drives Buy Rating on Strong Preclinical Wound and Burn Data in Large Underserved Markets - TipRanks
D. Boral Capital Reiterates 'Buy' Rating for FibroBiologics - National Today
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology - Bitget
Gainers Report: Is FibroBiologics Inc benefiting from interest rate changesQuarterly Portfolio Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
FibroBiologics sets new annual salary for CFO Jason D. Davis By Investing.com - Investing.com India
FibroBiologics Updates CFO Compensation to Support Leadership - TipRanks
FibroBiologics sets new annual salary for CFO Jason D. Davis - Investing.com
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - Sahm
FibroBiologics completes site onboarding for diabetic ulcer trial By Investing.com - Investing.com Canada
Top Executive Makes Bold Move Into FibroBiologics Stock - TipRanks
FibroBiologics completes site onboarding for diabetic ulcer trial - Investing.com
FibroBiologics (FBLG) CSO Khoja buys $11k in stock - Investing.com
FibroBiologics (FBLG) CSO Khoja buys $11k in stock By Investing.com - Investing.com Australia
FibroBiologics Completes Site Onboarding for Phase 1/2 - GlobeNewswire
CEO Doubles Down on FibroBiologics With Bold Insider Stock Purchase - TipRanks
FBLG Earnings History & Surprises | EPS & Revenue Results | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
FibroBiologics CFO Buys 70,000 Shares - National Today
CFO’s Bold Insider Buy Sparks Fresh Buzz Around FibroBiologics Stock - TipRanks
Davis Jason, FibroBiologics CFO, buys $28973 in FBLG stock By Investing.com - Investing.com Australia
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
Davis Jason, FibroBiologics CFO, buys $28973 in FBLG stock - Investing.com
FibroBiologics (FBLG) CFO purchases 70,000 shares in open-market trade - Stock Titan
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Newswire Canada
FibroBiologics receives patent for osteoporosis cell therapy By Investing.com - Investing.com Canada
Insider Makes Bold New Bet on FibroBiologics Stock - TipRanks
FBLG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FibroBiologics Jumps 22% On New Osteoporosis Patent, Stock Up - Nasdaq
Garcia Ruben A, FibroBiologics general counsel, buys $13k in FBLG - Investing.com Australia
FibroBiologics receives patent for osteoporosis cell therapy - Investing.com
FibroBiologics, Inc. announces issuance of U.S. patent covering fibroblast cell therapy for the treatment of osteoporosis - marketscreener.com
Fibrobiologics, Inc. Announces Issuance Of U.S. Patent Covering Fibroblast Cell Therapy For The Treatment Of Osteoporosis - TradingView
FibroBiologics, Inc. Announces Issuance of U.S. Patent - GlobeNewswire
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis - Bitget
FBLG: Ready to Transition to Clinical-Stage Company - Smartkarma
Fibrobiologics Inc (FBLG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):